Search results for "Hyperbilirubinemia"

showing 4 items of 4 documents

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

[Pharmacogenomics of antiretrovirals].

2008

HIV infection is a serious but treatable disease, yet current treatment is limited by development of resistance and high rates of adverse drug reactions. Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured. Increasing knowledge about genes implicated in pharmacokinetics, mode of action, efficacy, and toxicity of drugs has already provided relevant results for clinical practice, for example: The strong association of the abacavir hypersensitivity reaction with HLA-B*5701 permits testing patients for the allele, and if present avoiding the drug and therefore preventing the reaction. Persons with …

CyclopropanesDrugEfavirenzPyridinesmedia_common.quotation_subjectAtazanavir SulfateDiseaseBioinformaticsDrug HypersensitivityPatents as Topicchemistry.chemical_compoundPharmacokineticsCentral Nervous System DiseasesHLA AntigensAbacavirDrug Resistance ViralDrug DiscoveryMedicineHumansGenetic Predisposition to DiseasePharmacology (medical)Genetic TestingNevirapineGlucuronosyltransferaseDyslipidemiasHyperbilirubinemiamedia_commonRitonavirbusiness.industryPatient SelectionArea under the curveOxidoreductases N-DemethylatingGeneral MedicineDideoxynucleosidesBenzoxazinesHypersensitivity reactionCytochrome P-450 CYP2B6Infectious DiseaseschemistryAnti-Retroviral AgentsPharmacogeneticsAlkynesPharmacogenomicsAryl Hydrocarbon HydroxylasesbusinessOligopeptidesmedicine.drugMedicina clinica
researchProduct

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: resul…

2013

Purpose Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20+/CD22+ B-cell non-Hodgkin lymphoma (NHL). Patients and Methods A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NH…

OncologyAdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentFollicular lymphomaPharmacologyAntibodies Monoclonal HumanizedDrug Administration Schedulechemistry.chemical_compoundAntibodies Monoclonal Murine-Derivedimmune system diseasesRecurrenceRisk Factorshemic and lymphatic diseasesInternal medicineCalicheamicinAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInotuzumab OzogamicinMolecular Targeted TherapyB-cell lymphomaAgedHyperbilirubinemiaInotuzumab ozogamicinChemotherapybusiness.industryLymphoma Non-HodgkinMiddle Agedmedicine.diseasePrognosisThrombocytopeniaPolatuzumab vedotinLymphomaTreatment OutcomeOncologychemistryLiverRituximabFemalebusinessRituximabLiver Failuremedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

The determination of haemoglobin as cyanhaemiglobin or as alkaline haematin D-575. Comparison of method-related errors.

1989

In order to compare the accuracy of haemoglobin (Hb) determination methods, the commonly used cyanhaemiglobin (HiCN) method and the recently developed alkaline haematin D-575 (AHD) method (R. Zander, W. Lang & H. U. Wolf (1984) Clin. Chim. Acta 136, 83-93; H. U. Wolf, W. Lang & R. Zander (1984) Clin. Chim. Acta 136, 95-104) were tested with respect to method-related errors such as plasma, cell, and Hb errors. Both methods yield a series of more or less significant errors which generally lead to an overestimation of the Hb concentration in the order of 1%. However, in all three cases of plasma errors, i.e. normal plasma error, plasma error in lipaemic blood, and plasma error in bilirubinaemi…

educationBiochemistry (medical)Clinical BiochemistryErythrocyte MembraneAnalytical chemistryHyperlipidemiasGeneral MedicineBiologyHaematinRed blood cellchemistry.chemical_compoundHemoglobinsmedicine.anatomical_structurechemistryCarboxyhemoglobinPredictive Value of TestsBlood plasmamedicineLeukocytesDetermination methodsHumansHemoglobinFetal HemoglobinHyperbilirubinemiaJournal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie
researchProduct